Glenmede Trust Co. NA held its position in Becton, Dickinson and Company (NYSE:BDX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,233 shares of the medical instruments supplier’s stock at the end of the first quarter. Glenmede Trust Co. NA’s holdings in Becton, Dickinson and were worth $3,680,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in BDX. BlackRock Inc. boosted its stake in Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares during the period. Vanguard Group Inc. boosted its stake in Becton, Dickinson and by 5.3% in the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after buying an additional 796,034 shares during the period. JPMorgan Chase & Co. boosted its stake in Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after buying an additional 242,081 shares during the period. Wells Fargo & Company MN boosted its stake in Becton, Dickinson and by 1.2% in the first quarter. Wells Fargo & Company MN now owns 3,283,068 shares of the medical instruments supplier’s stock valued at $602,246,000 after buying an additional 39,362 shares during the period. Finally, Fundsmith LLP boosted its stake in Becton, Dickinson and by 3.2% in the first quarter. Fundsmith LLP now owns 2,296,613 shares of the medical instruments supplier’s stock valued at $421,291,000 after buying an additional 71,691 shares during the period. 75.71% of the stock is owned by institutional investors.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded up 0.9235% on Friday, reaching $200.0506. The company had a trading volume of 291,062 shares. The stock has a market capitalization of $45.52 billion, a PE ratio of 57.9353 and a beta of 1.05. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63. The company has a 50 day moving average price of $198.75 and a 200 day moving average price of $187.49.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $3.06 billion. During the same period in the previous year, the business earned $2.35 EPS. The company’s revenue was down 5.1% on a year-over-year basis. On average, equities research analysts anticipate that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be issued a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a dividend yield of 1.47%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

ILLEGAL ACTIVITY WARNING: “Glenmede Trust Co. NA Has $3,680,000 Stake in Becton, Dickinson and Company (NYSE:BDX)” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/11/glenmede-trust-co-na-has-3680000-stake-in-becton-dickinson-and-company-nysebdx.html.

BDX has been the topic of several analyst reports. Royal Bank Of Canada restated a “hold” rating and set a $177.00 price objective on shares of Becton, Dickinson and in a report on Thursday, April 13th. Evercore ISI upgraded Becton, Dickinson and from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $186.00 to $200.00 in a report on Monday, April 24th. Zacks Investment Research cut Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, May 4th. Raymond James Financial, Inc. upgraded Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price objective for the stock from $210.00 to $180.00 in a report on Friday, June 30th. Finally, Cowen and Company restated an “outperform” rating and set a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Monday, July 10th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $195.79.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now directly owns 12,861 shares in the company, valued at approximately $2,538,890.01. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Jeffrey S. Sherman sold 28,765 shares of the business’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now owns 70,821 shares in the company, valued at $13,171,289.58. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.